The current Quality Premium arrangements in relation to health care associated infections cover the incidence of both Meticillin-resistant Staphylococcus aureus (MRSA) bacteremia and Clostridium difficile (C. difficile) infection. 12.5% of the Quality Premium payment value is available to clinical commissioning groups (CCGs) for whom there are no reported cases of MRSA bacteraemia assigned to the CCG and for whom their reported C. difficile cases are at or below the defined thresholds for that CCG. In this way CCGs are: currently incentivised to work with their provider organisations to prevent any cases of MRSA bacteraemia and to deliver continued reductions in C difficile cases.
The NHS Outcomes Framework exists to provide a national level overview of how well the national health service is performing, to provide an accountability mechanism between the Secretary of State and NHS England for the effective spend of NHS funds and to act as a catalyst for driving up quality throughout the NHS by encouraging a change in culture and behaviour. Domain 5 of the NHS Outcomes Framework relates to patient safety and includes two indicators in relation to health care associated infections, covering the incidence of MRSA and the incidence of C difficile. This ensures that improvements in relation to health care associated infections are considered a priority for the work of NHS England and the wider NHS.